These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 28239031)
1. CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues. Yamakawa Y; Kusuhara M; Terashima M; Kinugasa Y; Sugino T; Abe M; Mochizuki T; Hatakeyama K; Kami K; Yamaguchi K Biomed Res; 2017; 38(1):41-52. PubMed ID: 28239031 [TBL] [Abstract][Full Text] [Related]
2. CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. Suenaga M; Yamada S; Fuchs BC; Fujii T; Kanda M; Tanaka C; Kobayashi D; Fujiwara M; Tanabe KK; Kodera Y J Surg Oncol; 2015 Nov; 112(6):622-8. PubMed ID: 26416034 [TBL] [Abstract][Full Text] [Related]
3. Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation. Jogo T; Oki E; Nakanishi R; Ando K; Nakashima Y; Kimura Y; Saeki H; Oda Y; Maehara Y; Mori M Gastric Cancer; 2021 Sep; 24(5):1089-1099. PubMed ID: 33963958 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer. Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396 [TBL] [Abstract][Full Text] [Related]
5. Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer. Aso T; Matsuo M; Kiyohara H; Taguchi K; Rikimaru F; Shimokawa M; Segawa Y; Higaki Y; Umeno H; Nakashima T; Masuda M PLoS One; 2015; 10(3):e0116596. PubMed ID: 25751671 [TBL] [Abstract][Full Text] [Related]
6. Cancer stem cell marker in circulating tumor cells: expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer. Katoh S; Goi T; Naruse T; Ueda Y; Kurebayashi H; Nakazawa T; Kimura Y; Hirono Y; Yamaguchi A Anticancer Res; 2015 Jan; 35(1):239-44. PubMed ID: 25550556 [TBL] [Abstract][Full Text] [Related]
7. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. Hagiwara M; Kikuchi E; Tanaka N; Kosaka T; Mikami S; Saya H; Oya M BMC Cancer; 2018 Jan; 18(1):113. PubMed ID: 29385995 [TBL] [Abstract][Full Text] [Related]
8. CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer. Go SI; Ko GH; Lee WS; Kim RB; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS Cancer Res Treat; 2016 Jan; 48(1):142-52. PubMed ID: 25779358 [TBL] [Abstract][Full Text] [Related]
9. The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation. Akamine T; Tagawa T; Ijichi K; Toyokawa G; Takamori S; Hirai F; Okamoto T; Oda Y; Maehara Y Ann Surg Oncol; 2019 May; 26(5):1544-1551. PubMed ID: 30798450 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characterisation of duodenal adenocarcinoma with high CD44 variant 9 expression. Maruyama Y; Uehara T; Daikuhara S; Kobayashi Y; Nakajima T; Matsumoto A; Tanaka E; Ota H Pathology; 2015 Dec; 47(7):647-52. PubMed ID: 26517627 [TBL] [Abstract][Full Text] [Related]
11. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Hirata K; Suzuki H; Imaeda H; Matsuzaki J; Tsugawa H; Nagano O; Asakura K; Saya H; Hibi T Br J Cancer; 2013 Jul; 109(2):379-86. PubMed ID: 23778530 [TBL] [Abstract][Full Text] [Related]
12. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression. Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933 [TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer. Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044 [TBL] [Abstract][Full Text] [Related]
14. Metabolomic profiling of gastric cancer tissues identified potential biomarkers for predicting peritoneal recurrence. Kaji S; Irino T; Kusuhara M; Makuuchi R; Yamakawa Y; Tokunaga M; Tanizawa Y; Bando E; Kawamura T; Kami K; Ohashi Y; Zhang S; Orita H; Lee-Okada HC; Fukunaga T; Terashima M Gastric Cancer; 2020 Sep; 23(5):874-883. PubMed ID: 32219586 [TBL] [Abstract][Full Text] [Related]
15. The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer. Go SI; Ko GH; Lee WS; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS Cancer Res Treat; 2019 Oct; 51(4):1411-1419. PubMed ID: 30913874 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of intraperitoneal CD44 mRNA levels of magnetically separated CD45-negative EpCAM-positive cells for peritoneal recurrence and prognosis in stage II and III gastric cancer patients. Horikawa M; Iinuma H; Inoue T; Ogawa E; Fukushima R Oncol Rep; 2011 May; 25(5):1413-20. PubMed ID: 21331451 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of HOXA10 promotes gastric cancer cells proliferation and HOXA10(+)/CD44(+) is potential prognostic biomarker for gastric cancer. Han Y; Lu S; Wen YG; Yu FD; Zhu XW; Qiu GQ; Tang HM; Peng ZH; Zhou CZ Eur J Cell Biol; 2015 Dec; 94(12):642-52. PubMed ID: 26552644 [TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of Tensin4 expression in human gastric cancer. Sakashita K; Mimori K; Tanaka F; Kamohara Y; Inoue H; Sawada T; Hirakawa K; Mori M Ann Surg Oncol; 2008 Sep; 15(9):2606-13. PubMed ID: 18612693 [TBL] [Abstract][Full Text] [Related]
19. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells. Mashima T; Iwasaki R; Kawata N; Kawakami R; Kumagai K; Migita T; Sano T; Yamaguchi K; Seimiya H Br J Cancer; 2019 Nov; 121(10):846-856. PubMed ID: 31607750 [TBL] [Abstract][Full Text] [Related]
20. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer. Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]